SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Rachel Carson

PatientRachel Carson
Date of birth1973-05-27
IdentifiersMRN HR-ML041-SYN; SSN (made up) 000-41-5068
Document date2026-04-20
AuthorMargaret Vance-Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review two weeks after left lumpectomy, with the pathology. [S]

History of Present Illness

Ms. Carson returns two weeks after a left lumpectomy with sentinel lymph node biopsy. The germline panel before surgery showed no pathogenic variant. She asked to hear the pathology in full and had it from Dr. Solís-Abernathy last week, and again today: the cancer was 2.3 cm, grade 2, with clear margins, and two of the three sentinel lymph nodes contained cancer, without spread beyond the node capsules (pT2 pN1a, anatomic stage IIB). She was told plainly that the cancer had reached lymph nodes under the arm, that this raises the chance of it returning, and that treatment is still given with the aim of cure. The recurrence score is 17. Last week the multidisciplinary breast team (surgery, medical oncology, and radiation oncology) reviewed the results and gave her their recommendations with the expected benefits and side effects in numbers; she took a week to read about them and has decided. The urea breath test three days ago, two weeks after she stopped omeprazole, was negative. The wound has healed and she has little pain on acetaminophen. She is writing again in the mornings. [S]

ElementDetail
Interval changeLeft lumpectomy and sentinel node biopsy two weeks ago
PathologypT2 pN1a(sn), 2 of 3 sentinel nodes, grade 2, margins clear; recurrence score 17
GeneticsNo pathogenic germline variant
Her decisionsRadiation; letrozole with ribociclib; zoledronic acid; no chemotherapy
UlcerUrea breath test negative; Helicobacter pylori eradicated

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy returning
IntegumentaryNegativeWounds healed; no redness or fluid
MusculoskeletalPositiveMild tightness raising the left arm; knee stiffness unchanged; no bone pain
NeurologicalPositiveSmall patch of numbness on the inner left upper arm
GastrointestinalNegativeNo indigestion or black stools off omeprazole
PsychiatricPositiveSome worry about the lymph nodes, sleeping better; PHQ-9 4, GAD-7 5

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healingOne capsule once daily before breakfastOral route2026-01-19 to 2026-04-03completedS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2025-06-02activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height163cmS
2026-04-20Body weight58.6kgS
2026-04-20Body mass index (BMI) [Ratio]22.1kg/m2S
2026-04-20Systolic blood pressure122mm[Hg]S
2026-04-20Diastolic blood pressure76mm[Hg]S
2026-04-20Heart rate74/minS
2026-04-20Respiratory rate14/minS
2026-04-20Body temperature36.7CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-04-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell and composed
BreastsLeft lumpectomy scar at 2 o'clock and axillary incision healed; mild firmness under the scar; no fluid or erythema. Right breast normal
Lymph nodesNo palpable axillary or supraclavicular nodes
ExtremitiesArm circumference 25.5 cm on each side 10 cm above the elbow, the same as before surgery; left shoulder flexion 160 degrees
AbdomenSoft; no epigastric tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to heractiveconfirmed C50.412S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy bookedresolvedconfirmed N63.21S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D).
Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure plannedresolvedconfirmed K26.9S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date.
Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shoreactiveconfirmed M17.0S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private.
Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17activeconfirmed C77.3S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationPost-operative wound, shoulder, and arm checkAfter surgeryCompleted todayWounds healed; shoulder flexion 160 degrees; no seroma
LaboratorySurgical pathology and recurrence scoreAfter surgeryUp to datepT2 pN1a(sn), margins clear; recurrence score 17
LaboratoryGermline genetic testingAt diagnosisUp to dateNo pathogenic variant; result given before surgery
Self-managementDisclosure of the pathology and shared decision-makingAt every resultCompleted todayPathology given in full in plain words with a copy; benefits and harms of each treatment given in numbers; decisions made by her after a week to consider them
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted today25.5 cm on each side, unchanged from the pre-operative baseline; counseled on early signs
ReferralMedical and radiation oncologyAfter surgeryUp to dateSeen last week at the multidisciplinary breast clinic
ImagingCT, bone scan, or PET for distant spreadOnly with symptoms or clinical stage IIINot indicatedPathologic stage IIB without symptoms of spread
LaboratoryTumor markersNot recommended for early breast cancerNot indicatedNot ordered
Medication safetyRibociclib baseline ECG, blood count, liver tests, and electrolytesBefore the first doseDueAt the visit when letrozole and ribociclib start, after radiation
ImagingBone density (DXA)Baseline at aromatase inhibitor startOrderedBooked for the day letrozole starts
Medication safetyDental assessment before zoledronic acidBefore the first infusionOrderedDental check booked before the first infusion
SurveyDistress, depression, and anxiety screen (PHQ-9 and GAD-7)At periodic intervalsCompleted todayPHQ-9 4 and GAD-7 5
LaboratoryHelicobacter pylori test of cureAt least four weeks after antibiotics and two weeks off a proton pump inhibitorUp to dateUrea breath test three days ago: negative

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016); Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39(27):3056-3082 (2021); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2024;119(9):1730-1753 (2024)

Follow-up: Radiation starting in two weeks. Primary care visit after radiation, on the day letrozole and ribociclib start. Next scheduled visit 2026-06-15: start of letrozole, ribociclib, and zoledronic acid after radiation. [S]